Chapel Hill startup with ties to UNC lands rights to drug offering hope to cystic fibrosis patients

Posted Oct 27, 2019
Path BioAnalytics (PBA), a precision medicine startup with ties to UNC, has scored the rights to a new drug therapy offering hope to cystic fibrosis (CF) patients with rare mutations. PBA is a graduate of Launch Chapel Hill, an accelerator program based in Chapel Hill, as well as the Kenan Flagler Business School program Startup UNC. (WRAL Tech Wire)

Related: Campus Connections

Tar Heels Top Their Best Multi-Year Graduation Success Rate For Fifth Straight Year
UNC student-athletes established their highest multi-year graduation rates for the fifth straight year and set the record for the best single-year rate as reported in...
Thu Nov 21, 2024

Clouds Brewing opens new location on Franklin Street, replacing Gizmo Brew Works
Clouds Brewing, a Triangle-based brewery, opened a third location on Franklin Street, replacing the space previously occupied by Gizmo Brew Works. On August 14, Gizmo...
Wed Nov 20, 2024

20 Years of the Carolina Covenant
Established in 2004, the Carolina Covenant is a financial aid package and network of support that provides an opportunity for students to graduate from the...
Sun Nov 17, 2024

10 things every UNC fan must do when visiting Chapel Hill
Locals call it Blue Heaven and it doesn’t take long to understand why. Virtually everything in town is painted the color of the sky. Even...
Fri Nov 15, 2024